Ensysce Biosciences, Inc. insider trading
Every open-market purchase and sale by Ensysce Biosciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $444,135 2 trades by 1 insider
3 months later: median −35.6% (−40.1% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Ensysce Biosciences, Inc.’s insiders pay?
From January 17, 2018 to August 18, 2026, 3 insiders reported 6 open-market purchases and 0 sales not made under a pre-set plan in Ensysce Biosciences, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Gower Bob G | Director | 4 | — | — | 0 | — | August 18, 2026 |
| Hg Vora Capital Management, LLC | 10% owner | 1 | — | — | 0 | — | January 17, 2018 |
| Kirkpatrick Lynn | Chief Executive Officer | 1 | — | — | 0 | — | May 27, 2022 |